P. Bertino, M. Carbone, and H. Pass, Chemotherapy of malignant pleural mesothelioma, Expert Opin Pharmacother, vol.10, pp.99-107, 2009.

P. G. Betta, C. Magnani, T. Bensi, N. F. Trincheri, and S. Orecchia, Immunohistochemistry and molecular diagnostics of pleural malignant mesothelioma, Arch Pathol Lab Med, vol.136, pp.253-61, 2012.

N. Boisgerault, F. Tangy, and M. Gregoire, New perspectives in cancer virotherapy: bringing the immune system into play, Immunotherapy, vol.2, pp.185-99, 2010.
URL : https://hal.archives-ouvertes.fr/pasteur-00507434

V. C. Broaddus, J. I. Everitt, B. Black, and A. B. Kane, Non-neoplastic and neoplastic pleural endpoints following fiber exposure, J Toxicol Environ Health B Crit Rev, vol.14, pp.153-78, 2011.

A. Cristaudo, A. Bonotti, S. Simonini, R. Bruno, and R. Foddis, Soluble markers for diagnosis of malignant pleural mesothelioma, Biomark Med, vol.5, pp.261-73, 2011.

R. E. Favoni, A. Daga, P. Malatesta, and T. Florio, Preclinical studies identify novel targeted pharmacological strategies for treatment of human malignant pleural mesothelioma, Br J Pharmacol, vol.166, pp.532-53, 2012.

M. Gregoire, What's the place of immunotherapy in malignant mesothelioma treatments?, Cell Adh Migr, vol.4, pp.153-61, 2010.

A. R. Haas and D. H. Sterman, Novel intrapleural therapies for malignant diseases, Respiration, vol.83, pp.277-92, 2012.

S. Huang, M. C. Jaurand, D. W. Kamp, J. Whysner, and T. Hei, Role of mutagenicity in asbestos fiber-induced carcinogenicity and other diseases, Journal of Toxicology and Environmental Health, vol.14, pp.1-67, 2011.

A. N. Husain, T. Colby, N. Ordonez, T. Krausz, and R. Attanoos, Guidelines for Pathologic Diagnosis of Malignant Mesothelioma: 2012 Update of the Consensus Statement from the International Mesothelioma Interest Group, Arch Pathol Lab Med, 2012.

, IARC monographs on the evaluation of the carcinogenic risk of chemicals to man: asbestos (chrysotile, amosite, crocidolite,tremolite, actinolite, and anthophyllite, IARC Monogr Eval Carcinog Risk Chem Man, vol.14, pp.1-106, 2012.

J. N. Jakobsen and J. B. Sorensen, Review on clinical trials of targeted treatments in malignant mesothelioma, Cancer Chemother Pharmacol, vol.68, pp.1-15, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00694874

B. Jasani and A. Gibbs, Mesothelioma not associated with asbestos exposure, Arch Pathol Lab Med, vol.136, pp.262-269, 2012.

D. Jean, J. Daubriac, L. Pimpec-barthes, F. Galateau-salle, F. et al., Molecular changes in mesothelioma with an impact on prognosis and treatment, Arch Pathol Lab Med, vol.136, pp.277-93, 2012.
URL : https://hal.archives-ouvertes.fr/inserm-02478588

A. B. Kane, Animal models of malignant mesothelioma, Inhal Toxicol, vol.18, pp.1001-1005, 2006.

L. Vecchia, C. Boffetta, and P. , Role of stopping exposure and recent exposure to asbestos in the risk of mesothelioma, Eur J Cancer Prev, vol.21, pp.227-257, 2012.
URL : https://hal.archives-ouvertes.fr/hal-01262920

F. Lopez-rios, P. B. Illei, V. Rusch, and M. Ladanyi, Evidence against a role for SV40 infection in human mesotheliomas and high risk of false-positive PCR results owing to presence of SV40 sequences in common laboratory plasmids, Lancet, vol.364, pp.1157-66, 2004.

S. P. Oviedo and P. T. Cagle, Diffuse malignant mesothelioma, Arch Pathol Lab Med, vol.136, pp.882-890, 2012.

B. W. Robinson, A. W. Musk, and R. A. Lake, Malignant mesothelioma, Lancet, vol.366, pp.397-408, 2005.

V. W. Rusch, D. Giroux, C. Kennedy, E. Ruffini, and A. K. Cangir, Initial Analysis of the International Association For the Study of Lung Cancer Mesothelioma Database, J Thorac Oncol, vol.7, pp.1631-1639, 2012.

A. Scherpereel, P. Astoul, P. Baas, T. Berghmans, and H. Clayson, Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma, Eur Respir J, vol.35, pp.479-95, 2010.

G. T. Stathopoulos and I. Kalomenidis, Animal models of malignant pleural effusion, Curr Opin Pulm Med, vol.15, pp.343-52, 2009.

D. J. Sugarbaker and A. S. Wolf, Surgery for malignant pleural mesothelioma, Expert Rev Respir Med, vol.4, pp.363-72, 2010.

A. Vachani, E. Moon, and S. M. Albelda, Gene therapy for mesothelioma, Curr Treat Options Oncol, vol.12, pp.173-80, 2011.

W. Weder, I. Opitz, and R. Stahel, Multimodality strategies in malignant pleural mesothelioma, Semin Thorac Cardiovasc Surg, vol.21, pp.172-178, 2009.

M. Andersson, H. Wallin, M. Jonsson, and L. L. Nielsen, Lung carcinoma and malignant mesothelioma in patients exposed to thorotrast : incidence, histology and p53 status, Int J Cancer, vol.63, pp.330-336, 1995.

K. M. Bang, G. A. Pinheiro, J. M. Wood, and G. Syamlal, Malignant mesothelioma mortality in the United States, Int J Occup Environ Health, vol.12, pp.9-15, 1999.

J. E. Below, N. J. Cox, N. K. Fukagawa, A. Hirvonen, and J. R. Testa, Factors that impact susceptibility to fiberinduced health effects, J Toxicol Environ Health B Crit Rev, vol.14, pp.246-66, 2011.

G. Berry, N. H. De-klerk, A. Reid, G. L. Ambrosini, and L. Fritschi, Malignant pleural and peritoneal mesotheliomas in former miners and millers of crocidolite at Wittenoom, Western Australia, Occup Environ Med, vol.61, p.14, 2004.

C. Bianchi and T. Bianchi, Malignant mesothelioma: global incidence and relationship with asbestos, Ind Health, vol.45, pp.379-87, 2007.

V. Bourdes, P. Boffetta, and P. Pisani, Environmental exposure to asbestos and risk of pleural mesothelioma: review and meta-analysis, Eur J Epidemiol, vol.16, pp.411-418, 2000.

M. Carbone, H. I. Pass, L. Miele, and M. Bocchetta, New developments about the association of SV40 with human mesothelioma, Oncogene, vol.22, pp.5173-5180, 2003.

A. Cavazza, L. B. Travis, W. D. Travis, J. T. Wolfe, and M. L. Foo, Post-irradiation malignant mesothelioma, Cancer, vol.77, pp.1379-1385, 1996.

P. Comba, A. Gianfagna, and L. Paoletti, Pleural mesothelioma cases in Biancavilla are related to a new fluoroedenite fibrous amphibole, Arch Environ Health, vol.58, pp.229-261, 2003.

N. De-klerk, H. Alfonso, N. Olsen, A. Reid, and J. Sleith, Familial aggregation of malignant mesothelioma in former workers and residents of Wittenoom, Western Australia, Int J Cancer, 2012.

V. Delgermaa, K. Takahashi, E. K. Park, G. V. Le, and T. Hara, Global mesothelioma deaths reported to the World Health Organization between, Bull World Health Organ, vol.89, pp.724-724, 1994.

M. Goldberg, E. Imbernon, P. Rolland, G. Soit-ilg, A. Saves et al., The French National Mesothelioma Surveillance Program, Occup Environ Med, vol.63, pp.390-395, 2006.

K. Hemminki and S. Hussain, Mesothelioma incidence has leveled off in Sweden, Int J Cancer, vol.122, pp.1200-1201, 2008.

M. Huncharek, Non-asbestos related diffuse malignant mesothelioma, Tumori, vol.88, pp.1-9, 2002.

, IARC monographs on the evaluation of the carcinogenic risk of chemicals to man: asbestos (chrysotile, amosite, crocidolite,tremolite, actinolite, and anthophyllite, IARC Monogr Eval Carcinog Risk Chem Man, vol.14, pp.1-106, 2012.

A. G. Ilg, J. Bignon, and A. J. Valleron, Estimation of the past and future burden of mortality from mesothelioma in France, Occup Environ Med, vol.55, pp.760-765, 1998.

B. Jasani and A. Gibbs, Mesothelioma not associated with asbestos exposure, Arch Pathol Lab Med, vol.136, pp.262-269, 2012.

L. Stang, N. L. Belot, A. , S. Ilg, A. G. Rolland et al., Evolution of pleural cancers and malignant pleural mesothelioma incidence in France between 1980 and, Int J Cancer, vol.126, pp.232-238, 2005.
URL : https://hal.archives-ouvertes.fr/hal-00698003

J. Leigh and T. Driscoll, Malignant mesothelioma in Australia, Int J Occup Environ Health, vol.9, pp.206-223, 1945.

M. M. Maule, C. Magnani, P. Dalmasso, D. Mirabelli, and F. Merletti, Modeling mesothelioma risk associated with environmental asbestos exposure, Environ Health Perspect, vol.115, pp.1066-71, 2007.

J. C. Mcdonald and A. D. Mcdonald, The epidemiology of mesothelioma in historical context, Eur Respir J, vol.9, pp.1932-1974, 1996.

S. Metintas, M. Metintas, I. Ucgun, and U. Oner, Malignant mesothelioma due to environmental exposure to asbestos: follow-up of a Turkish cohort living in a rural area, Chest, vol.122, pp.2224-2233, 2002.

T. Murayama, K. Takahashi, Y. Natori, and N. Kurumatani, Estimation of future mortality from pleural malignant mesothelioma in Japan based on an age-cohort model, Am J Ind Med, vol.49, pp.1-7, 2006.

S. Pitarque, R. Cleries, J. M. Martinez, G. Lopez-abente, and M. Kogevinas, Mesothelioma mortality in men: trends during 1977-2001 and projections for 2002-2016 in Spain, Occup Environ Med, vol.65, pp.279-82, 2008.

B. Price, Analysis of current trends in United States mesothelioma incidence, Am J Epidemiol, vol.145, pp.211-219, 1997.

B. Price and A. Ware, Mesothelioma trends in the United States: an update based on Surveillance, Epidemiology, and End Results Program data for 1973 through, Am J Epidemiol, vol.159, pp.107-119, 2003.

B. Price and A. Ware, Time trend of mesothelioma incidence in the United States and projection of future cases: An update based on SEER data for 1973 through, Crit Rev Toxicol, vol.39, pp.576-88, 2005.

C. Rake, C. Gilham, J. Hatch, A. Darnton, and J. Hodgson, Occupational, domestic and environmental mesothelioma risks in the British population: a case-control study, Br J Cancer, vol.100, pp.1175-83, 2009.

S. P. Riaz, V. H. Coupland, M. Luchtenborg, M. D. Peake, and H. Moller, Mesothelioma incidence projections in South East England, Eur Respir J, vol.40, pp.965-973, 2012.

P. Rolland, C. Gramond, A. Lacourt, P. Astoul, &. Chamming et al., Occupations and industries in France at high risk for pleural mesothelioma: A population-based case-control study, Am J Ind Med, vol.53, pp.1207-1226, 1998.

I. Roushdy-hammady, J. Siegel, S. Emri, J. R. Testa, and M. Carbone, Genetic-susceptibility factor and malignant mesothelioma in the Cappadocian region of Turkey, Lancet, vol.357, pp.444-449, 2001.

O. Segura, A. Burdorf, and C. Looman, Update of predictions of mortality from pleural mesothelioma in the Netherlands, Occup Environ Med, vol.60, pp.50-55, 2003.

E. Tan, N. Warren, A. J. Darnton, and J. T. Hodgson, Projection of mesothelioma mortality in Britain using Bayesian methods, Br J Cancer, vol.103, pp.430-436, 2010.

L. B. Travis, S. D. Fossa, S. J. Schonfeld, M. L. Mcmaster, and C. F. Lynch, Second cancers among 40,576 testicular cancer patients: focus on long-term survivors, J Natl Cancer Inst, vol.97, pp.1354-65, 2005.

J. D. Tward, M. M. Wendland, D. C. Shrieve, A. Szabo, and D. K. Gaffney, The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma, Cancer, vol.107, pp.108-123, 2006.

G. Van-kaick, A. Dalheimer, S. Hornik, A. Kaul, and D. Liebermann, The german thorotrast study: recent results and assessment of risks, Radiat Res, vol.152, pp.64-71, 1999.

J. C. Wagner, C. A. Sleggs, and P. Marchand, Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province, Br J Ind Med, vol.17, pp.260-271, 1960.

H. Weill, J. Hughes, and A. Churg, Changing trends in US mesothelioma incidence, Occup Environ Med, vol.62, p.270, 2005.

H. Weill, J. M. Hughes, and A. M. Churg, Changing trends in US mesothelioma incidence, Occup Environ Med, vol.61, pp.438-479, 2004.

, CLINICAL ASPECTS

J. M. Alvarez, A. Hasani, A. Segal, G. Sterret, and M. Millward, Bilateral thoracoscopy, mediastinoscopy and laparoscopy, in addition to CT, MRI and PET imaging, are essential to correctly stage and treat patients with mesothelioma prior to trimodality therapy, ANZ J Surg, vol.79, pp.734-742, 2009.

N. P. Campbell and H. L. Kindler, Update on malignant pleural mesothelioma, Semin Respir Crit Care Med, vol.32, pp.102-112, 2011.

R. M. Flores, H. I. Pass, V. E. Seshan, J. Dycoco, and M. Zakowski, Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients, J Thorac Cardiovasc Surg, vol.135, pp.1-3, 2008.

F. Gueugnon, S. Leclercq, C. Blanquart, C. Sagan, and L. Cellerin, Identification of novel markers for the diagnosis of malignant pleural mesothelioma, Am J Pathol, vol.178, pp.1033-1075, 2011.

K. Hollevoet, J. B. Reitsma, J. Creaney, B. D. Grigoriu, and B. W. Robinson, Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis, J Clin Oncol, vol.30, pp.1541-1550, 2012.

S. C. Kao, G. Reid, N. Van-zandwijk, D. W. Henderson, and S. Klebe, Molecular biomarkers in malignant mesothelioma: state of the art, Pathology, vol.43, pp.201-213, 2011.

S. Klebe and D. W. Henderson, Early stages of mesothelioma, screening and biomarkers. Recent Results Cancer Res, vol.189, pp.169-93, 2011.

M. R. Law, M. E. Hodson, and B. E. Heard, Malignant mesothelioma of the pleura: relation between histological type and clinical behaviour, Thorax, vol.37, pp.810-815, 1982.

C. Lee, N. Bayman, R. Swindell, and C. Faivre-finn, Prophylactic radiotherapy to intervention sites in mesothelioma: a systematic review and survey of UK practice, Lung Cancer, vol.66, pp.150-156, 2009.

R. Menzies and M. Charbonneau, Thoracoscopy for the diagnosis of pleural disease, Ann Intern Med, vol.114, pp.271-277, 1991.

H. I. Pass, S. M. Levin, M. R. Harbut, J. Melamed, and L. Chiriboga, Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma, N Engl J Med, vol.367, pp.1417-1444, 2012.

U. B. Prakash and H. M. Reiman, Comparison of needle biopsy with cytologic analysis for the evaluation of pleural effusion: analysis of 414 cases, Mayo Clin Proc, vol.60, pp.158-64, 1985.

B. W. Robinson, C. Robinson, and R. A. Lake, Localised spontaneous regression in mesothelioma --possible immunological mechanism, Lung Cancer, vol.32, pp.197-201, 2001.

C. Robinson, M. Callow, S. Stevenson, B. Scott, and B. W. Robinson, Serologic responses in patients with malignant mesothelioma: evidence for both public and private specificities, Am J Respir Cell Mol Biol, vol.22, pp.550-556, 2000.

V. W. Rusch, A proposed new international TNM staging system for malignant pleural mesothelioma, From the International Mesothelioma Interest Group. Chest, vol.108, pp.1122-1130, 1995.

A. Scherpereel, B. Grigoriu, M. Conti, T. Gey, and M. Gregoire, Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma, Am J Respir Crit Care Med, vol.173, pp.1155-60, 2006.

B. Scott, S. Mukherjee, R. A. Lake, B. Robinson, and M. Mesothelioma, Textbook of Lung Cancer, pp.271-293, 2000.

D. J. Sugarbaker, R. M. Flores, M. T. Jaklitsch, W. G. Richards, and G. M. Strauss, Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients, J Thorac Cardiovasc Surg, vol.117, pp.54-63, 1999.

D. J. Sugarbaker, M. T. Jaklitsch, R. Bueno, W. Richards, and J. Lukanich, Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies, J Thorac Cardiovasc Surg, vol.128, pp.138-184, 2004.

D. S. Trousse, J. P. Avaro, D. 'journo, X. B. Doddoli, C. Astoul et al., Is malignant pleural mesothelioma a surgical disease? A review of 83 consecutive extra-pleural pneumonectomies, Eur J Cardiothorac Surg, vol.36, pp.759-63, 2009.

, MORPHOLOGICAL CLASSIFICATION

R. L. Attanoos, S. D. Dojcinov, R. Webb, and A. R. Gibbs, Anti-mesothelial markers in sarcomtoid mesothelioma and other spindle cell neoplasms, Histopathol, vol.37, pp.224-231, 2000.

R. L. Attanoos, A. Griffin, and A. R. Gibbs, The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium. A novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet-derived growth factor-receptor, P-glycoprotein and Bcl-2, Histopathology, vol.43, pp.231-239, 2003.

A. Churg, P. Cagle, and V. Roggli, Diffuse malignant tumors of the serosal membranes, American Registry of Pathology, 2006.

A. Churg, T. V. Colby, P. Cagle, J. Corson, and A. R. Gibbs, The separation of benign and malignant mesothelial proliferations, Am J Surg Pathol, vol.24, pp.1183-200, 2000.

A. Churg and F. Galateau-salle, The separation of benign and malignant mesothelial proliferations, Arch Pathol Lab Med, vol.136, pp.1217-1243, 2012.

F. Galateau-sallé, E. Brambilla, P. T. Cagle, A. M. Churg, and T. V. Colby, Pathology of Malignant Mesothelioma, 2006.

J. King, N. Thatcher, C. Pickering, and P. Hasleton, Sensitivity and specificity of immunohistochemical antibodies used to distinguish between benign and malignant pleural disease: a systematic review of published reports, Histopathology, vol.49, pp.561-569, 2006.

S. Klebe and D. W. Henderson, Early stages of mesothelioma, screening and biomarkers. Recent Results Cancer Res, vol.189, pp.169-93, 2011.

, Pathology genetics of tumours of the lung, pleura, thymus and heart, WHO, 2004.

V. Agarwal, M. J. Lind, and L. Cawkwell, Targeted epidermal growth factor receptor therapy in malignant pleural mesothelioma: Where do we stand?, Cancer Treat Rev, 2011.

H. Benjamin, D. Lebanony, S. Rosenwald, L. Cohen, and H. Gibori, A diagnostic assay based on microRNA expression accurately identifies malignant pleural mesothelioma, J Mol Diagn, vol.12, pp.771-780, 2010.

M. Bott, M. Brevet, B. S. Taylor, S. Shimizu, and T. Ito, The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma, Nat Genet, vol.43, pp.668-72, 2011.

R. Bueno, A. De-rienzo, L. Dong, G. J. Gordon, and C. F. Hercus, Second generation sequencing of the mesothelioma tumor genome, PLoS One, vol.5, p.10612, 2010.

S. Busacca, S. Germano, D. Cecco, L. Rinaldi, M. Comoglio et al., MicroRNA signature of malignant mesothelioma with potential diagnostic and prognostic implications, Am J Respir Cell Mol Biol, vol.42, pp.312-321, 2010.

B. C. Christensen, E. A. Houseman, J. J. Godleski, C. J. Marsit, and J. L. Longacker, Epigenetic profiles distinguish pleural mesothelioma from normal pleura and predict lung asbestos burden and clinical outcome, Cancer Res, vol.69, pp.227-261, 2009.

B. C. Christensen, E. A. Houseman, G. M. Poage, J. J. Godleski, and R. Bueno, Integrated Profiling Reveals a Global Correlation between Epigenetic and Genetic Alterations in Mesothelioma, Cancer Res, vol.70, pp.5686-5694, 2010.

G. V. Gee, D. C. Koestler, B. C. Christensen, D. J. Sugarbaker, and D. Ugolini, Downregulated microRNAs in the differential diagnosis of malignant pleural mesothelioma, Int J Cancer, vol.127, pp.2859-69, 2010.

G. J. Gordon, G. N. Rockwell, R. V. Jensen, J. G. Rheinwald, and J. N. Glickman, Identification of novel candidate oncogenes and tumor suppressors in malignant pleural mesothelioma using large-scale transcriptional profiling, Am J Pathol, vol.166, pp.1827-1867, 2005.

Y. Goto, K. Shinjo, Y. Kondo, L. Shen, and M. Toyota, Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma, Cancer Res, vol.69, pp.9073-82, 2009.

S. G. Gray, D. A. Fennell, L. Mutti, O. Byrne, and K. J. , In arrayed ranks: array technology in the study of mesothelioma, J Thorac Oncol, vol.4, pp.411-436, 2009.

M. Guled, L. Lahti, P. M. Lindholm, K. Salmenkivi, and I. Bagwan, CDKN2A, NF2, and JUN are dysregulated among other genes by miRNAs in malignant mesothelioma -A miRNA microarray analysis, Genes Chromosomes Cancer, vol.48, pp.615-638, 2009.

C. D. Hoang, D. 'cunha, J. Kratzke, M. G. Casmey, C. E. Frizelle et al., Gene expression profiling identifies matriptase overexpression in malignant mesothelioma, Chest, vol.125, pp.1843-52, 2004.

D. Jean, E. Thomas, A. Renier, A. De-reynies, and C. Lecomte, Syntenic relationships between genomic profiles of fiber-induced murine and human malignant mesothelioma, Am J Pathol, vol.176, pp.881-894, 2011.
URL : https://hal.archives-ouvertes.fr/inserm-00531343

Y. W. Kong, D. Ferland-mccollough, T. J. Jackson, and M. Bushell, 2012) microRNAs in cancer management, Lancet Oncol, vol.13, pp.249-58

M. Krismann, K. M. Muller, M. Jaworska, and G. Johnen, Molecular cytogenetic differences between histological subtypes of malignant mesotheliomas: DNA cytometry and comparative genomic hybridization of 90 cases, J Pathol, vol.197, pp.363-71, 2002.

F. Lopez-rios, S. Chuai, R. Flores, S. Shimizu, and T. Ohno, Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction, Cancer Res, vol.66, pp.2970-2979, 2006.

M. Musti, E. Kettunen, S. Dragonieri, P. Lindholm, and D. Cavone, Cytogenetic and molecular genetic changes in malignant mesothelioma, Cancer Genet Cytogenet, vol.170, pp.9-15, 2006.

H. I. Pass, C. Goparaju, S. Ivanov, J. Donington, and M. Carbone, ) hsa-miR-29c* Is Linked to the Prognosis of Malignant Pleural Mesothelioma, Cancer Res, vol.70, pp.1916-1924, 2010.

J. S. Reis-filho and L. Pusztai, Gene expression profiling in breast cancer: classification, prognostication, and prediction, Lancet, vol.378, pp.1812-1835, 2011.

S. Romagnoli, E. Fasoli, V. Vaira, M. Falleni, and C. Pellegrini, Identification of potential therapeutic targets in malignant mesothelioma using cell-cycle gene expression analysis, Am J Pathol, vol.174, pp.762-70, 2009.

Y. Sekido, Inactivation of Merlin in malignant mesothelioma cells and the Hippo signaling cascade dysregulation, Pathol Int, vol.61, pp.331-375, 2011.

S. Singhal, R. Wiewrodt, L. D. Malden, K. M. Amin, and K. Matzie, Gene expression profiling of malignant mesothelioma, Clin Cancer Res, vol.9, pp.3080-97, 2003.

D. J. Sugarbaker, W. G. Richards, G. J. Gordon, L. Dong, D. Rienzo et al., Transcriptome sequencing of malignant pleural mesothelioma tumors, Proc Natl Acad Sci U S A, vol.105, pp.3521-3527, 2008.

M. Suzuki, S. Toyooka, N. Shivapurkar, H. Shigematsu, and K. Miyajima, Aberrant methylation profile of human malignant mesotheliomas and its relationship to SV40 infection, Oncogene, vol.24, pp.1302-1310, 2005.

Y. Suzuki, H. Murakami, K. Kawaguchi, T. Taniguchi, and M. Fujii, Activation of the PI3K-AKT pathway in human malignant mesothelioma cells, Molecular Medicine Reports, vol.2, pp.181-188, 2009.

S. Toyooka, H. I. Pass, N. Shivapurkar, Y. Fukuyama, and R. Maruyama, Aberrant methylation and simian virus 40 Tag sequences in malignant mesothelioma, Cancer Res, vol.61, pp.5727-5730, 2001.

J. Zucman-rossi, Molecular classification of hepatocellular carcinoma, Dig Liver Dis, vol.42, pp.235-276, 2010.
URL : https://hal.archives-ouvertes.fr/inserm-00497516

, MESOTHELIOMA THERAPY

P. Astoul, E. Roca, F. Galateau-salle, and A. Scherpereel, Malignant pleural mesothelioma: from the bench to the bedside, Respiration, vol.83, pp.481-93, 2012.

E. H. Baldini, A. Recht, G. M. Strauss, M. M. Decamp, J. Swanson et al., Patterns of failure after trimodality therapy for malignant pleural mesothelioma, Ann Thorac Surg, vol.63, pp.334-342, 1997.

P. Bertino, C. Porta, D. Barbone, S. Germano, and S. Busacca, Preliminary data suggestive of a novel translational approach to mesothelioma treatment: imatinib mesylate with gemcitabine or pemetrexed, Thorax, vol.62, pp.690-695, 2007.

N. P. Campbell, R. Kunnavakkam, N. Leighl, M. D. Vincent, and D. R. Gandara, Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium, Lung Cancer, vol.78, pp.76-80, 2012.

J. F. Cortese, A. L. Gowda, A. Wali, J. F. Eliason, and H. I. Pass, Common EGFR mutations conferring sensitivity to gefitinib in lung adenocarcinoma are not prevalent in human malignant mesothelioma, Int J Cancer, vol.118, pp.521-523, 2006.

J. Creaney, D. Yeoman, Y. Demelker, A. Segal, and A. W. Musk, Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma, J Thorac Oncol, vol.3, pp.851-858, 2008.

J. E. Dowell, F. R. Dunphy, R. N. Taub, D. E. Gerber, and L. Ngov, A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma, Lung Cancer, vol.77, pp.567-71, 2012.

S. Dubey, P. A. Janne, L. Krug, H. Pang, and X. Wang, A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307, J Thorac Oncol, vol.5, pp.1655-61, 2010.

A. Z. Dudek, H. Pang, R. A. Kratzke, G. A. Otterson, and L. Hodgson, Phase II study of dasatinib in patients with previously treated malignant mesothelioma (cancer and leukemia group B 30601): a brief report, J Thorac Oncol, vol.7, pp.755-764, 2010.

F. Ebstein, C. Sapede, P. J. Royer, M. Marcq, and C. Ligeza-poisson, Cytotoxic T cell responses against mesothelioma by apoptotic cell-pulsed dendritic cells, Am J Respir Crit Care Med, vol.169, pp.1322-1352, 2004.

A. J. Frew, R. W. Johnstone, and J. E. Bolden, Enhancing the apoptotic and therapeutic effects of HDAC inhibitors, Cancer Lett, vol.280, pp.125-158, 2009.

R. Gaafar, A. Bahnassy, I. Abdelsalam, M. M. Kamel, and A. Helal, Tissue and serum EGFR as prognostic factors in malignant pleural mesothelioma, Lung Cancer, 2010.

L. L. Garland, C. Rankin, D. R. Gandara, S. E. Rivkin, and K. M. Scott, Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study, J Clin Oncol, vol.25, pp.2406-2419, 2007.

A. Gauvrit, S. Brandler, C. Sapede-peroz, N. Boisgerault, and F. Tangy, Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response, Cancer Res, vol.68, pp.4882-92, 2008.
URL : https://hal.archives-ouvertes.fr/pasteur-00330770

G. J. Gordon, M. Mani, G. Maulik, L. Mukhopadhyay, and B. Y. Yeap, Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma, Cancer Chemother Pharmacol, vol.61, pp.549-58, 2008.

R. Govindan, R. A. Kratzke, J. E. Herndon, G. A. Niehans, and R. Vollmer, Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B, Clin Cancer Res, vol.11, pp.2300-2304, 2005.

M. Gregoire, C. Ligeza-poisson, N. Juge-morineau, and R. Spisek, Anti-cancer therapy using dendritic cells and apoptotic tumour cells: pre-clinical data in human mesothelioma and acute myeloid leukaemia, Vaccine, vol.21, pp.791-795, 2003.

V. Gregorc, P. A. Zucali, A. Santoro, G. L. Ceresoli, and G. Citterio, Phase II study of asparagine-glycinearginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma, J Clin Oncol, vol.28, pp.2604-2615, 2010.

B. D. Grigoriu, A. Scherpereel, P. Devos, B. Chahine, and M. Letourneux, Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment, Clin Cancer Res, vol.13, pp.2928-2963, 2007.

M. L. Hartman, J. M. Esposito, B. Y. Yeap, and D. J. Sugarbaker, Combined treatment with cisplatin and sirolimus to enhance cell death in human mesothelioma, J Thorac Cardiovasc Surg, vol.139, pp.1233-1273, 2010.

R. Hassan, T. Bera, and I. Pastan, Mesothelin: a new target for immunotherapy, Clin Cancer Res, vol.10, pp.3937-3979, 2004.

R. Hassan, S. Bullock, A. Premkumar, R. J. Kreitman, and H. Kindler, Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers, Clinical cancer research : an official journal of the American Association for Cancer Research, vol.13, pp.5144-5153, 2007.

R. Hassan, C. Schweizer, K. F. Lu, B. Schuler, and A. T. Remaley, Inhibition of mesothelin-CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapy, Lung Cancer, vol.68, pp.455-464, 2010.

J. P. Hegmans, J. D. Veltman, M. E. Lambers, I. J. De-vries, and C. G. Figdor, Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma. American journal of respiratory and critical care medicine, vol.181, pp.1383-90, 2010.

V. Izzi, L. Masuelli, I. Tresoldi, C. Foti, and A. Modesti, Immunity and malignant mesothelioma: from mesothelial cell damage to tumor development and immune response-based therapies. Cancer letters, vol.322, pp.18-34, 2012.

D. M. Jackman, H. L. Kindler, B. Y. Yeap, P. Fidias, and R. Salgia, Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma, Cancer, vol.113, pp.808-822, 2008.

T. Jahan, L. Gu, R. Kratzke, A. Dudek, and G. A. Otterson, Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107), Lung Cancer, vol.76, pp.393-399, 2012.

K. Kai, S. Costa, R. C. Sills, and Y. Kim, Inhibition of the insulin-like growth factor 1 receptor pathway enhances the antitumor effect of cisplatin in human malignant mesothelioma cell lines, Cancer Lett, vol.278, pp.49-55, 2009.

H. L. Kindler, T. G. Karrison, D. R. Gandara, C. Lu, and L. M. Krug, Multicenter, double-blind, placebocontrolled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma, J Clin Oncol, vol.30, pp.2509-2524, 2012.

J. Kurai, H. Chikumi, K. Hashimoto, M. Takata, and T. Sako, Therapeutic antitumor efficacy of antiepidermal growth factor receptor antibody, cetuximab, against malignant pleural mesothelioma, Int J Oncol, vol.41, pp.1610-1618, 2012.

S. A. Laurie, A. Gupta, Q. Chu, C. W. Lee, and W. Morzycki, Brief report: a phase II study of sunitinib in malignant pleural mesothelioma. the NCIC Clinical Trials Group, J Thorac Oncol, vol.6, pp.1950-1954, 2011.

S. Leclercq, F. Gueugnon, B. Boutin, F. Guillot, and C. Blanquart, A 5-aza-2'-deoxycytidine/valproate combination induces cytotoxic T-cell response against mesothelioma, Eur Respir J, vol.38, pp.1105-1121, 2011.

A. Mathy, P. Baas, O. Dalesio, and N. Van-zandwijk, Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial, Lung Cancer, vol.50, pp.83-89, 2005.

M. J. Mccoy, A. K. Nowak, and R. A. Lake, Chemoimmunotherapy: an emerging strategy for the treatment of malignant mesothelioma, Tissue Antigens, vol.74, pp.1-10, 2009.

C. W. Mulatero, R. T. Penson, D. Papamichael, N. H. Gower, and M. Evans, A phase II study of combined intravenous and subcutaneous interleukin-2 in malignant pleural mesothelioma, Lung Cancer, vol.31, pp.67-72, 2001.

K. J. O'byrne, S. Danson, D. Dunlop, N. Botwood, and F. Taguchi, Combination therapy with gefitinib and rofecoxib in patients with platinum-pretreated relapsed non small-cell lung cancer, J Clin Oncol, vol.25, pp.3266-73, 2007.

H. I. Pass, D. Lott, F. Lonardo, M. Harbut, and Z. Liu, Asbestos exposure, pleural mesothelioma, and serum osteopontin levels, N Engl J Med, vol.353, pp.1564-73, 2005.

A. Powell, J. Creaney, S. Broomfield, I. Van-bruggen, and B. Robinson, Recombinant GM-CSF plus autologous tumor cells as a vaccine for patients with mesothelioma, Lung Cancer, 2006.

S. S. Ramalingam, R. A. Parise, R. K. Ramanathan, T. F. Lagattuta, and L. A. Musguire, Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies, Clin Cancer Res, vol.13, pp.3605-3615, 2007.

A. Scherpereel, T. Berghmans, J. J. Lafitte, B. Colinet, and M. Richez, Valproate-doxorubicin: promising therapy for progressing mesothelioma. A phase II study, Eur Respir J, vol.37, pp.129-164, 2011.

D. H. Sterman, A. Haas, E. Moon, A. Recio, and D. Schwed, A trial of intrapleural adenoviral-mediated Interferon-alpha2b gene transfer for malignant pleural mesothelioma, Am J Respir Crit Care Med, vol.184, pp.1395-1404, 2011.

D. H. Sterman, A. Recio, A. Vachani, J. Sun, and L. Cheung, Long-term follow-up of patients with malignant pleural mesothelioma receiving high-dose adenovirus herpes simplex thymidine kinase/ganciclovir suicide gene therapy, Clin Cancer Res, vol.11, pp.7444-53, 2005.

T. Treasure, L. Lang-lazdunski, D. Waller, J. M. Bliss, and C. Tan, Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study, Lancet Oncol, vol.12, pp.763-72, 2011.

F. Vandermeers, P. Hubert, P. Delvenne, C. Mascaux, and B. Grigoriu, Valproate, in combination with pemetrexed and cisplatin, provides additional efficacy to the treatment of malignant mesothelioma, Clin Cancer Res, vol.15, pp.2818-2846, 2009.

W. Weder, R. A. Stahel, P. Baas, U. Dafni, and M. De-perrot, The MARS feasibility trial: conclusions not supported by data, Lancet Oncol, vol.12, pp.1093-1097, 2011.

A. Yasumitsu, C. Tabata, R. Tabata, N. Hirayama, and A. Murakami, Clinical significance of serum vascular endothelial growth factor in malignant pleural mesothelioma, J Thorac Oncol, vol.5, pp.479-83, 2010.

P. A. Zucali, G. L. Ceresoli, D. Vincenzo, F. Simonelli, M. Lorenzi et al., Advances in the biology of malignant pleural mesothelioma, Cancer Treat Rev, vol.37, pp.543-58, 2011.

. Animal and . Vitro-models,

J. E. Craighead, N. J. Akley, L. B. Gould, and B. L. Libbus, Characteristics of tumors and tumor cells cultured from experimental asbestos-induced mesotheliomas in rats, Am J Pathol, vol.129, pp.448-62, 1987.

J. Daubriac, J. Fleury-feith, L. Kheuang, J. Galipon, and A. Saint-albin, Malignant pleural mesothelioma cells resist anoikis as quiescent pluricellular aggregates, Cell Death and Differentiation, vol.16, pp.1146-1155, 2009.
URL : https://hal.archives-ouvertes.fr/inserm-00388174

M. R. Davis, L. S. Manning, D. Whitaker, M. J. Garlepp, and B. Robinson, Establishment of a Murine Model of Malignant Mesothelioma, Intl J Cancer, vol.52, pp.881-886, 1992.

M. Giovannini, E. Robanus-maandag, M. Van-der-valk, M. Niwa-kawatika, and V. Abramowski, Conditional biallelic N?2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2, iMig 2012 meeting Abstract Book, vol.14, pp.1617-1630, 2000.

J. Jongsma, E. Van-montfort, M. Vooijs, J. Zevenhoven, and P. Krimpenfort, A conditional mouse model for malignant mesothelioma, Cancer Cell, vol.13, pp.261-71, 2008.

C. Robinson, I. Van-bruggen, A. Segal, M. Dunham, and A. Sherwood, A novel SV40 TAg transgenic model of asbestos-induced mesothelioma: malignant transformation is dose dependent, Cancer Res, vol.66, pp.10786-94, 2006.